Ultragenyx Pharma (RARE) Misses Q2 EPS by 2c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- US stock futures rise as oil pullback amplifies Fed rate-hike boost
- Oil prices extend losses as supply disruption fears ease
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Ultragenyx Pharma (RARE) PT Lowered to $66 at Citi
August 5, 2019 6:26 AM EDTCiti analyst Yigal Nochomovitz lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $66.00 (from $69.00) while maintaining a Neutral rating.
... MoreUltragenyx Pharma (RARE) Announces Submission of NDA to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders
August 1, 2019 8:31 AM EDTUltragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for UX007 (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), a group of genetic disorders in which the body is unable to convert long-chain fatty acids into energy. The FDA previously granted Rare Pediatric Disease Designation and Fast Track designation, which enables eligibility for Priority Review, if relevant criteria... More
